Drug intelligence / Profile preview

Endosera

Development stage
Unknown
Lead developer
Seragen Biotherapeutics
Modality
Peptides
Administration
Vaginal
01

Overview

Endosera is an autologous, cell-free, standardized platelet-derived growth factor (PDGF) concentrate developed by Seragen Biotherapeutics. It is designed as a co-adjuvant therapy for women with recurrent implantation failure (RIF) and refractory thin endometrium undergoing assisted reproductive techniques (ART). The preparation is optimized for the proliferation, secretion, and implantation phases of the endometrium, containing 6–9 times higher concentrations of growth factors compared to peripheral blood. By promoting angiogenesis, immunomodulation, and tissue repair, Endosera aims to restore endometrial receptivity and improve clinical pregnancy and live birth rates in patients who have failed conventional treatments.

Brand names
Endosera
Other names
Autologous platelet-derived growth factor therapyAutologous Platelet Derived Growth Factors
02

Targets

IGF-1R (Insulin-like growth factor 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)TGFBR (TGF-beta receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)

Beyond the preview

Go deeper on Endosera.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endosera.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call